TKIs Appear Safe in Patients With Chronic Myeloid Leukemia, CKD
the ONA take:
Tyrosine kinase inhibitors (TKIs) seem safe in patients with chronic myeloid leukemia (CML) in chronic-phase and chronic kidney disease, a recent study published online ahead of print in the journal Cancer has shown.
For the study, researchers investigated the incidence of acute injury and chronic kidney disease in 468 patients with newly diagnosed chronic-phase CML who were treated with imatinib, dasatinib, or nilotinib.
Results showed that 4% of patients experienced TKI-associated acute kidney injury. Researchers found that imatinib was associated with an increased incidence of acute kidney injury compared with dasatinib and nilotinib.
The study also demonstrated that 14% of patients developed chronic kidney disease while receiving TKI treatment. Of those, 84% were receiving imatinib. However, in patients with a history of chronic kidney disease, imatinib did not cause a significant decline in glomerular filtration rate.
"The administration of TKIs may be safe in the setting of CKD in CP CML patients, but close monitoring is still warranted," Musa Yilmaz, M.D., from the Baylor College of Medicine in Houston, TX, and colleagues wrote.
Tyrosine kinase inhibitors seem safe in patients with chronic myeloid leukemia in chronic-phase and chronic kidney disease.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|